Harbin Pharmaceutical Group Co., Ltd. Sustainability Profile
Harbin Pharmaceutical Group Co., Ltd., commonly referred to as Harbin Pharma, is a leading player in the pharmaceutical industry, headquartered in Harbin, China. Established in 1997, the company has made significant strides in the development and production of a wide range of pharmaceutical products, including traditional Chinese medicine, chemical drugs, and biopharmaceuticals. With a strong presence in both domestic and international markets, Harbin Pharma is renowned for its commitment to innovation and quality. The company’s core offerings include prescription medications, over-the-counter products, and health supplements, distinguished by their efficacy and adherence to stringent safety standards. Recognised for its robust research and development capabilities, Harbin Pharmaceutical Group has achieved notable milestones, positioning itself as a trusted name in healthcare. Its dedication to advancing medical solutions continues to enhance its reputation within the global pharmaceutical landscape.
DitchCarbon Score
How does Harbin Pharmaceutical Group Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Harbin Pharmaceutical Group Co., Ltd.'s score of 22 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Harbin Pharmaceutical Group Co., Ltd.'s reported carbon emissions
Harbin Pharmaceutical Group Co., Ltd., headquartered in China (CN), currently does not report any specific carbon emissions data for the most recent year. As such, there are no available figures for total emissions, including Scope 1, Scope 2, or Scope 3 emissions. Additionally, the company has not outlined any formal reduction targets or commitments related to carbon emissions. There are no initiatives reported under the Science Based Targets initiative (SBTi) or other climate pledges. Given the absence of emissions data and reduction initiatives, it is unclear how Harbin Pharmaceutical Group is addressing climate change within its operations. The company may need to enhance its transparency and commitment to sustainability to align with industry standards and expectations.
How Carbon Intensive is Harbin Pharmaceutical Group Co., Ltd.'s Industry?
How Carbon Intensive is Harbin Pharmaceutical Group Co., Ltd.'s Location?
Harbin Pharmaceutical Group Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Harbin Pharmaceutical Group Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
